Loading stock data…
GOSS
$0.37+0.00 (+0.54%)
Market ClosedLast close May 1
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gossamer Bio, Inc. in the Healthcare sector is trading at $0.37. The stock is currently near its 52-week low of $0.32, remaining 82.1% below its 200-day moving average. Technical signals show neutral RSI of 43 and bullish MACD crossover, explaining why GOSS maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.37
Potential Upside
5%
Whystock Fair Value$0.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$85.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
138.78%
Volume
Today's trading volume
2.27M
Recent News
How Mixed Trial Results And Balance Sheet Pressure Are Reframing The Gossamer Bio (GOSS) Story
The updated analyst model keeps Gossamer Bio’s Fair Value estimate steady at US$3.69 per share, even as assumptions around growth, profitability and risk shift under the surface. Street commentary links these unchanged targets to a tug of war between mixed seralutinib data, regulatory uncertainty, and balance sheet questions on one side, and a differentiated mechanism with upcoming catalysts on the other. As you read on, you will see how these factors shape the evolving story and what to...
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback
Gossamer Bio, Inc. (NASDAQ:GOSS) earns a spot on our list of the best penny stocks set to explode. As of April 8, 2026, sentiment around Gossamer Bio, Inc. (NASDAQ:GOSS) remains cautious, with 56% of covering analysts issuing “Hold” ratings on the stock. The consensus price target of $1 implies an upside of 203.31%. Gossamer Bio, […]
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral
Gossamer Bio, Inc. (NASDAQ:GOSS) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On March 23, 2026, Cantor Fitzgerald downgraded Gossamer Bio, Inc. (NASDAQ:GOSS) to Neutral from Overweight without a price target. Cantor Fitzgerald cited the negative Phase 3 PROSERA readout and an unclear regulatory path for seralutinib in pulmonary arterial […]
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the penny stocks with the potential to rise 1000 percent. Gossamer Bio remained in focus in March 2026 after its late-February Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension missed its primary endpoint, though the company said it planned to meet with the U.S. Food and […]
Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue
Gossamer Bio, Inc (NASDAQ:GOSS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. Gossamer Bio, Inc (NASDAQ:GOSS) reported its fourth-quarter results on March 17, delivering a mixed performance as earnings missed expectations while revenue came in stronger than expected. The company posted a GAAP loss of $0.21 per share, falling short […]